Fixed combination of oral NEPA (netupitant‐palonosetron) for the prevention of acute and delayed chemotherapy‐induced nausea and vomiting in patients receiving multiple cycles of chemotherapy: Efficacy data from 2 randomized, double‐blind phase III studies

AIM: To assess the efficacy of oral NEPA (netupitant‐palonosetron 300/0.50 mg) over multiple chemotherapy cycles. METHODS: Two randomized phase III studies evaluated a single dose of oral NEPA given on day 1 in chemotherapy‐naive patients receiving anthracycline‐cyclophosphamide (AC)–based (Study 1)...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwartzberg, Lee, Karthaus, Meinolf, Rossi, Giorgia, Rizzi, Giada, Borroni, Maria E., Rugo, Hope S., Jordan, Karin, Hansen, Vincent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536946/
https://www.ncbi.nlm.nih.gov/pubmed/30968588
http://dx.doi.org/10.1002/cam4.2091

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6536946/
https://www.ncbi.nlm.nih.gov/pubmed/30968588
http://dx.doi.org/10.1002/cam4.2091

Ejemplares similares